AxoGen, Inc. Appoints Lisa N. Colleran to Board of Directors
July 10 2018 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerves,
today announced it increased its Board of Directors to eight
members and appointed
Lisa N. Colleran as a
director to fill the newly created position. Colleran was also
appointed to the Audit Committee and the Governance and Nominating
Committee.
“Lisa brings proven medical device and health
care leadership, with strong market development and
commercialization experience in fast growing companies,” commented
Karen Zaderej, Chairman, Chief Executive Officer, and President.
“We are excited to have her join our team and will benefit greatly
from her valuable insights and passion for improving patient
quality of life.”
Colleran is a 30+ year health care industry veteran and the
former CEO, President, and Board member of LifeCell Corporation.
During her 11-year tenure, LifeCell became one of the most
successful medical device companies in plastic and general surgery.
Under her leadership, LifeCell experienced significant clinical and
commercial expansion, growing annual revenues from $25 million to
$400 million. Prior to joining LifeCell, she spent 20 years at
Baxter Healthcare in various commercial, business development, and
general management roles with increasing responsibilities. Colleran
is currently a Board member at Establishment Labs, an innovative
breast implant company, and Rockwell Medical, a specialty
pharmaceutical company focused on renal failure. She previously
served as a Board member for Novadaq Technologies, Inc. prior to
their acquisition by Stryker Corporation. Colleran has a Bachelor
of Science degree in Nursing from Molloy College in New York and an
MBA with a concentration in Marketing from Loyola University of
Chicago in Illinois.
“I look forward to working with Karen, the Board of
Directors, and the AxoGen team as they build the emerging
peripheral nerve repair market and bring much needed clinical
solutions to surgeons and their patients,” said Colleran.
About AxoGenAxoGen (AXGN) is the
leading company focused specifically on the science, development
and commercialization of technologies for peripheral nerve
regeneration and repair. We are passionate about helping to restore
peripheral nerve function and quality of life to patients with
physical damage or discontinuity to peripheral nerves by providing
innovative, clinically proven and economically effective repair
solutions for surgeons and health care providers. Peripheral nerves
provide the pathways for both motor and sensory signals throughout
the body. Every day, people suffer traumatic injuries or undergo
surgical procedures that impact the function of their peripheral
nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
AxoGen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, an off-the-shelf processed human nerve allograft for
bridging severed peripheral nerves without the comorbidities
associated with a second surgical site, AxoGuard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves, AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments, and Avive® Soft
Tissue Membrane, a minimally processed human umbilical cord
membrane that may be used as a resorbable soft tissue covering to
separate tissue layers and modulate inflammation in the surgical
bed. Along with these core surgical products, AxoGen also offers
AcroVal® Neurosensory & Motor Testing System and AxoTouch®
Two-Point Discriminator. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on peripheral nerve function. The AxoGen portfolio of
products is available in the United States, Canada, the United
Kingdom, and several other European and international
countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
“forward-looking” statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as “expects,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “projects,” “forecasts,”
“continue,” “may,” “should,” “will,” and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2018
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:AxoGen, Inc.Kaila Krum,
Vice President, Investor Relations and Corporate
Developmentkkrum@axogeninc.comInvestorRelations@AxoGenInc.com
Solebury Trout – Investor
Relations
Brian Korb 646.378.2923bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024